NFKB1 and acute lymphoblastic leukemia: Taken together, these results indicate that in T-ALL cell lines the bortezomib/CX-4945 combination induced an inhibition of the NF-κB pathway, whereas in B-ALL cells, the combined treatment triggered NF-κB signaling activation.